Surgical outcomes in gastroenterological surgery in Japan: Report of National Clinical database 2011–2016
Yoshihiro Kakeji(Kobe University), Yasuyuki Seto(Tokyo National Hospital), Harushi Udagawa(Okinaka Memorial Adult Disease Research Institute), Itaru Endo(Yokohama City University), Chikara Kunisaki(Yokohama City University), Tadahiko Masaki(Kyorin University), Mitsukazu Gotoh(Osaka Prefectural Medical Center), Kazuhiro Yoshida(Kyoto Institute of Technology), Akira Tangoku, Michiaki Unno(Tohoku University), Akinobu Taketomi(Hokkaido University), Hiroaki Miyata(The University of Tokyo), Shigeru Marubashi(Osaka International Cancer Institute), Hiroyuki Konno(Tokyo Health Care University), Arata Takahashi(Keio University)
Cited by 62
Related Papers
Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05)
|Japanese Journal of Clinical Oncology|2018|534
Randomized clinical trial of adjuvant gemcitabine chemotherapy <i>versus</i> observation in resected bile duct cancer
|British journal of surgery|2018|401
Clinical practice guidelines for the management of biliary tract cancers 2015: the 2<sup>nd</sup> English edition
|Journal of Hepato-Biliary-Pancreatic Sciences|2015|300
Interleukin‐6/<scp>STAT</scp>3 signaling as a promising target to improve the efficacy of cancer immunotherapy
|Cancer Science|2017|295
Genome-wide Association Study Identifies TNFSF15 and POU2AF1 as Susceptibility Loci for Primary Biliary Cirrhosis in the Japanese Population
|The American Journal of Human Genetics|2012|272